The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
Tal como se relató a Erica Rimlinger
Solía asistir a celebraciones navideñas todos los años tostada y brillando con un bronceado nuevo. Broncearme era parte de mi rutina regular de belleza y me sentía incompleta si no lo hacía. Nunca pensé que cancelaría mi membresía en el salón de bronceado al que fui durante mucho tiempo, pero ese día llegó.
El formulario de cancelación solicitaba un motivo. Escribí con letras grandes: MELANOMA. Tenía 26 años, me habían diagnosticado recientemente una de las formas más mortales de cáncer de la piel y estaba furiosa conmigo por ignorar las advertencias en letras pequeñas del contrato. El empleado del salón miró mi formulario después de que lo contesté, dijo, “está bien, ya acabaste” y se fue.
Días antes, mi mamá me rogó que haga que examinen un lunar en mi pecho. Estaba preocupada porque a mi papá le diagnosticaron melanoma de etapa 0 el mes anterior. Pensé que el diagnóstico de mi papá le estaba dando paranoia. Solo cinco semanas después de cumplir 26 años, era mucho más joven que mi papá y mi lunar sospechoso se veía como el de él. El mío no era grande como el lunar de mi papá, pero tenía varios colores con bordes irregulares.
Ignoré a mi mamá diciendo “seguro, mamá”, pero su preocupación se fijó en mi cerebro. Usé Google para investigar y vi muchas fotos de lunares sospechosos. Finalmente pensé, está bien, no pierdo nada si hago que un dermatólogo examine mi piel.
Estaba poco preparada para la experiencia de pararme desnuda, de cabeza a pies, frente a un doctor que conocí apenas cinco segundos antes. Tengo muchos lunares y a medida que el doctor los inspeccionaba, me preguntaba sobre mi uso de camas de bronceado, mis antecedentes familiares de melanoma y mis hábitos en lo que se refiere al sol. Empecé a sentirme incómoda y me puse un poco a la defensiva. Vivo en Ohio donde no recibimos mucho sol y broncearse es un estándar de belleza. No ves a modelos que no estén bronceadas, ¿verdad? El doctor me preguntó si tenía algún lunar que me preocupase. Obstinadamente, dije no.
2019
Sin embargo, se acercó a ver el que le preocupó a mi mamá. No se veía como mis otros lunares. Lo extrajo para una biopsia y pensé, “maravilloso. Ya acabamos”. Había escuchado de personas a quienes les removían lunares precancerosos todo el tiempo. Eso no significaba que ocurría algo malo. Mi mamá estaría feliz de que hayan examinado mi piel y debo admitir que yo también me sentía un poco mejor.
El doctor dijo que tendría los resultados en tres a cinco días laborales, pero pasaron 10 días y no me dijo nada. Llamé al consultorio y pregunté si perdieron mi lunar. El equipo médico pidió disculpas y dijo que lo enviaron para pruebas adicionales. Ahí es cuando sentí la primera sensación negativa.
En el 14º día después de la biopsia, estaba en el auto con mi esposo cuando el consultorio del dermatólogo llamó con mis resultados. El tono sombrío de la voz de mi doctor anunció el melanoma antes de decirlo con palabras. Afortunadamente mi esposo estaba manejando. Tenía melanoma de etapa 1a que estaba a punto de convertirse en etapa 1b. Lo primero que pensé fue, “esto es peor que el caso de mi papá”. Luego pensé, “¿cómo podía ser peor que el de mi papá?”. El doctor recomendó una cirugía inmediata y una prueba de los ganglios linfáticos. Toda la llamada duró menos de 10 minutos, pero mi rostro estaba pálido y mi mundo también perdió su color.
Dos semanas después de esa llamada telefónica, fui al hospital por ocho horas. Nunca antes me habían anestesiado. El único procedimiento médico que había tenido hasta entonces era la remoción de mis muelas del juicio. Desperté después de la cirugía con dos incisiones grandes y mucha pena por la vida que ya no tenía. Me encantaba broncearme. Y eso estaba arraigado profundamente en mi imagen corporal. Además de la pena, también estaba enojada conmigo, con el sol e incluso con el hábito de mi papá de quemarse cuando cortaba el césped o cuando jugaba golf.
Quería correr, levantar pesas y acostarme bajo el sol nuevamente. Los primeros dos deseos tendrían que esperar hasta que sane y el tercero ya no era una opción para mí. Debía cambiar mi estilo de vida y cancelar mi membresía al salón de bronceado.
Deje de tener pena por eso después de un mes y medio. Comprendí que eso no servía de nada y que tenía la oportunidad de aprender, cambiar mis hábitos y dar gracias por mi segunda oportunidad. Pero hacía esto en silencio, sin decirlo casi a nadie debido a la vergüenza que sentía por mi diagnóstico.
2024
Durante los dos siguientes años después de mi cirugía, me sometí frecuentemente a evaluaciones de mi piel y perdí la cuenta de las biopsias que tuve. Sentía como si estuviesen rebanando mi cuerpo. El peso de la carga mental, emocional y física de sobrevivir, hizo que comprenda que necesitaba apoyo. Era hora de compartir mi historia.
En las redes sociales, encontré #melanoma y me sorprendió cuantas personas que tenían un poco más de 20 años compartían historias de sus melanomas. Tomé una foto de mis cicatrices, la publiqué, entré en pánico y lancé el teléfono al otro lado del cuarto.
La mofa, vergüenza y mensajes de “te lo dije” que esperaba nunca aparecieron, ni siquiera una vez. En vez de eso, mi comunidad me dio amor y apoyo y yo estaba muy agradecida. Una vez que empecé a interactuar con otros sobrevivientes de melanoma y consejeros, mi carga se desvaneció.
Me alegra haber buscado apoyo cuando lo hice. El melanoma de mi papá reapareció en su cerebro y pulmones. Después de 21 rondas de inmunoterapia, radiación de bisturí de rayos y y varios viajes a la sala de emergencias, las lesiones de mi papá empezaron a encogerse. Actualmente, mi papá todavía está aquí y su melanoma ha desaparecido casi por completo. Estamos tan agradecidos y esta experiencia ha hecho que nuestra familia esté mucho más unida.
Leah y su padre en su matrimonio, junio de 2025. (Foto/Aisley Herndon
Ahora acepto el hecho de haber amado el sol. En vez de culparme en silencio, digo lo que siento y concientizo a otras personas para que se cuiden del sol y para que se sometan a examinaciones de la piel. Soy voluntaria en la Melanoma Research Foundation [Fundación de investigación del melanoma] y estoy en el comité de líderes de la Melanoma Research Alliance [Alianza de investigación del melanoma] (MRA). En lo que se refiere a la MRA, voy al capitolio cada año, a pedirle al congreso que proteja el financiamiento de investigaciones, que prohíba las camas de bronceado y que investigue de mejor forma los ingredientes de los protectores solares.
En vez de torturarme por no protegerme del sol cuando era adolescente y adulta joven, estoy trabajando para cambiar la cultura que motiva a las personas a que ignoren los riesgos de broncearse. Todavía asisto a las fiestas navideñas brillando, pero ahora con gratitud y no por haberme bronceado.
Este recurso educativo se preparó con el apoyo de Merck.
¿Eres una mujer con historias reales que te gustaría compartir? Avísanos
Nuestras historias son experiencias auténticas de mujeres reales. HealthyWomen no avala los puntos de vista, opiniones y experiencias expresados en estas historias y no reflejan necesariamente las políticas o posiciones oficiales de HealthyWomen.
From Your Site Articles
Related Articles Around the Web
Spot Gold hovers around $4,060 in the American session on Tuesday, easing from an intraday peak of $4,082. The XAU/USD pair is little changed for a second consecutive day, reflecting investors’ wait-and-see stance ahead of United States (US) data releases scheduled for later this week.
Following the US federal shutdown, the government was finally able to pass a funding bill last week, which means governmental offices resumed activity and hence, data collection.
Market participants are cautious ahead of the announcement, but also wary about earnings reports. Among other companies, Home Depot reported weakening sales growth and cut its outlook for the financial year, blaming the downturn in its performance on a sluggish housing market and weaker consumer sentiment.NVIDIA is also scheduled to report this week, and the results could disrupt financial markets, especially tech-related reports.
Other than that, the US published August Factory Orders, which were up 1.4% on a monthly basis, improving from the -1.3% posted in July. The data is old, but it helped maintain the US Dollar (USD) afloat ahead of more relevant macroeconomic figures.
Additionally, ADP released the four-week average on Employment Change, which showed US private employers shed an average of 2,500 jobs a week in the four weeks ending November 1.
From a technical point of view, the 4-hour chart shows XAU/USD trading at $4,067.90, up for the day. The 20-period Simple Moving Average (SMA) has turned lower, providing dynamic resistance at around $4,090. At the same time, the 200-period SMA continues to rise modestly, now standing at $4,074.85, while holding above the 100-period at $4,041.52, the latter providing relevant dynamic support. Meanwhile, the Momentum indicator remains below its midline but edges higher, indicating waning bearish pressure. Finally, the Relative Strength Index (RSI) stands neutral at 46.
In the daily chart, XAU/USD has posted a lower high and a lower low, hinting at increased selling interest without confirming an upcoming decline. The 20-day SMA has turned lower, while the 100- and 200-day SMAs continue to rise, keeping the broader trend supported. Price holds above all these averages, suggesting buyers retain the upper hand. Technical indicators hold within positive levels, with the Momentum rising above its midline, and the RSI holding neutral around 52 with scope to extend if bulls press the advantage. The pair needs to recover beyond the $4,100 level to become more attractive to bulls, an unlikely scenario at the time being.
(The technical analysis of this story was written with the help of an AI tool)
While matcha green tea is often hailed as a trendy superfood with numerous health benefits, it can actually be significantly harmful for some people, as one woman discovered when she found herself in hospital. Laura Mae shared her experience on TikTok from her hospital bed, where she was being treated for iron deficiency.
In a video that has since gone viral, amassing more than 10 million views, she attributed her ill health to her daily consumption of matcha. “When you realise the matcha you have been drinking every morning is likely the reason your hair is falling out,” she captioned the video.
Laura Mae went on to explain: “Matcha can block your body’s natural iron absorption, which can increase hair loss, brittle nails, and fatigue.”
In a subsequent video, she revealed that she used to attribute all her health issues to her Crohn’s Disease. However, once she considered her regular intake of matcha, everything started to make sense, reports the Mirror.
“Once I realised my daily matcha was making iron absorption even harder, it all clicked,” said Laura Mae. “Swapping my morning drink was the best change I’ve made.”
She added: “Gut health really is everything. Once I changed my morning routine, the symptoms finally started to make sense.”
Following her discharge from hospital, Laura Mae shared with her followers: “Not every ‘healthy habit’ is healthy for everybody. For me, matcha was secretly making things worse, especially with absorption already being a struggle.
“Once I swapped it out, I noticed the difference in my energy and mood almost immediately. I didn’t realise how much my daily matcha was holding me back until I swapped it for something my body actually thanked me for.”
Supporting Laura’s worries, Verywell Health cautions that matcha contains tannins and other compounds which can hinder iron absorption.
“Matcha is a type of powdered green tea well known for its high antioxidant content,” the organisation states online.
“It also contains a unique combination of caffeine and L-theanine, a natural amino acid that has been shown to help with energy, stress, and focus, often making it a gentler alternative to coffee.
“[Tannins are] a type of polyphenol that can bind iron in the digestive tract, making it harder for the body to absorb. Because matcha is much more concentrated than regular green tea, it contains more of these polyphenols that will block your body from absorbing iron.”
Meanwhile, Matcha.com also cautions: “According to research, matcha tea does contain compounds that may limit the absorption of iron in the bloodstream. If you are concerned about your iron levels and at risk of iron anemia, try to avoid drinking your matcha or green tea after or within an hour of an iron-rich meal or iron supplements.
“This is because the main healthful compounds found in matcha tea will bind to iron and cause both to lose their ability to be as readily absorbed.”
XRP’s price is down – but its fundamentals are hotter than ever. Canary’s XRPC ETF launched with a bang last week, attracting $58 million in opening-day volume. The move reflects deep institutional interest – and excitement is growing, with Franklin Templeton’s XRP ETF set to launch today.
Despite ETF tailwinds, the XRP price followed the broader market into bearish territory this week, falling 12% to $2.15 today. However, with institutional appeal clearly there, could we see XRP rebound in the weeks ahead?
Our XRP price prediction aims to evaluate the potential impact these ETFs could have on the asset’s short- and long-term pricing dynamics. We’ll consider both the historical performance of other cryptos with ETFs and analyst opinions.
But as the market focuses on XRP, analysts have spotted another crypto that’s currently flying under the radar – but could offer massive upside. It’s called Maxi Doge (MAXI), and it’s building traction in its presale at an impressive pace, raising $4 million thus far.
This publication is sponsored. CryptoDnes does not endorse and is not responsible for the content, accuracy, quality, advertising, products or other materials on this page.
Canary’s XRPC ETF burst out of the gate with $245 million of creations (new shares of the ETF) on day one. ETF expert Eric Balchunas declared that both XRPC and the newly listed Bitwise Solana ETF BSOL “are in a league of their own,” with no other 2025 ETF launch coming close to their initial momentum, reflecting deep investor appetite for mainstream altcoin exposure.
Congrats to $XRPC for $58m in Day One volume, the most of any ETF launched this year (out of 900), BARELY edging out $BSOL‘s $57m. The two of them are in league of own tho as 3rd place is over $20m away. pic.twitter.com/MjsOeceeNb
— Eric Balchunas (@EricBalchunas) November 13, 2025
The crypto analyst Diana underlined that Franklin Templeton is next in line to launch its XRP ETF today. This will be followed by Bitwise on Thursday, then 21Shares, CoinShares, Grayscale, and WisdomTree – all within the next week.
🚨UPDATE: FRANKLIN TEMPLETON’S XRP ETF (EZRP) GOES LIVE TUESDAY 🚨
…and Bitwise is right behind it on November 20. 😳🔥
Franklin Templeton (@FTI_US) — a $1.5 TRILLION asset manager — is launching its $XRP ETF (EZRP) on the CBOE THIS TUESDAY.
Analysts are already saying EZRP… pic.twitter.com/tMV70zsTQT
— Diana (@InvestWithD) November 16, 2025
Both Bitcoin and Ethereum ETF launches in 2024 demonstrated a similar dynamic to what we’ve seen so far with XRP and Solana: strong institutional demand, but negative immediate price movements. However, the long-term effects of ETF demand helped fuel the BTC and ETH rallies during this market cycle.
It took Bitcoin less than one month after its January 2024 ETF launch to gain bullish momentum, whereas it took Ethereum between 4 months and a year, due to intermittent volatility.
Judging by Canary’s ETF launch, Franklin Templeton and other issuers are likely to drive significant fresh demand into XRP, which could help fuel the next rally – especially if the broader market rebounds. But what are analysts saying?
Steph Is Crypto notes that XRP has a deep liquidation cluster above $3, suggesting that the price could move in this direction next.
However, Crypto Fergani suggests that the rally could extend toward $6. One reason this analysis holds credibility is that unlike other major cryptos such as Bitcoin, Ethereum, and Solana, XRP has successfully defended its key $2 support level despite the crash, providing structural strength that could enable a stronger rebound.
XRP’s combination of institutional appeal, upside liquidity risk, and structural chart strength is an exciting setup. It makes the project one of the standout players in line for an aggressive rebound. But as optimism builds, another project analysts believe is poised for substantial gains is Maxi Doge – so let’s look at what it’s all about.
Maxi Doge (MAXI) is undergoing a presale – and it’s on fire. The project has successfully raised over $4 million so far, fueled by rising investor appetite as projects already listed on exchanges struggle.
It’s branded around Dogecoin’s Shiba Inu motif, but introduces an entirely new concept. Futures trading integrations, community rewards, and degen-themed branding are its three main pillars.
The team plans to integrate MAXI into perpetual futures platforms, allowing users to trade it with leverage in both directions if they wish. There will also be weekly trading competitions, where MAXI holders with the highest trading ROI receive free tokens, adding an interactive, competitive element to the project.

Furthermore, the team plans to run community activation events to boost holder engagement. It has also added a staking mechanism to the presale that provides passive rewards, currently valued at a 76% APY.
With over $4 million raised, it’s clear that a lot of investors have belief in Maxi Doge’s potential. And leading analysts do too: Alessandro De Crypto recently predicted MAXI could see 100x gains, for example.
The past few months have been rough for crypto. Bitcoin has slid 28% from its ATH, and most altcoins have taken even bigger hits. But with institutional capital now flowing into altcoin ETFs, the tide may finally be turning.
If bullish momentum rekindles, XRP hitting $6 in the coming months is a real possibility. Meanwhile, Maxi Doge’s early-stage positioning, fast-growing presale, and innovative meme-utility approach give it the potential to deliver even larger upside.
This publication is sponsored. CryptoDnes does not endorse and is not responsible for the content, accuracy, quality, advertising, products or other materials on this page. Readers should do their own research before taking any action related to cryptocurrencies. CryptoDnes shall not be liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with use of or reliance on any content, goods or services mentioned.
A biosimilar is a medicine that is similar to an existing, brand name biologic medicine (a medicine made from living cells and organisms). Although biosimilars are not identical copies of biologics, they’re very close and work in the same way.
Like biologics, biosimilars have many different uses, including treating certain types of cancer.
We spoke with Gury Doshi, M.D., medical director at Texas Oncology-Houston West and chair of The US Oncology Network Pharmacy and Therapeutics committee, to learn more about these promising treatments.
Biologics are medicines that are made up of living cells or organisms. That’s why they’re called biologics — bio meaning living cells. Some examples of biologics are gene therapies, stem cell therapies, monoclonal antibodies and recombinant proteins.
These medicines are used to treat chronic conditions, including autoimmune disorders like rheumatoid arthritis, lupus and Crohn’s disease, as well as some cancers.
A generic medication is an exact chemical copy of a medicine, with identical active ingredients. It’s not possible to make an exact copy of a biologic since they’re made from a living source, so biosimilars are as close as you can get. There are slight differences between the two, but not enough to affect their structure or function.
Yes, absolutely. The FDA won’t allow a biosimilar on the market unless they see data showing safety and effectiveness. After the medicine has been approved, they continue to keep an eye on it to make sure it’s safe and works the way it should.
The approval process for a biosimilar is an abbreviated process. When the FDA is deciding whether to approve a biosimilar, they don’t look at how chemically close the medicine is to the biologic it’s modeled after. They only look at whether the biosimilar is safe and effective.
The fact that biologics are made from living cells and organisms is what makes them special, but it also makes them a little more expensive to develop. Since biosimilars are based on a biologic as opposed to being invented from scratch, they don’t cost as much to make. This savings often gets passed on to patients.
Having a cheaper but just as effective alternative to biologics means we can offer these treatments to more patients and get them started sooner — which may ultimately lead to better outcomes.
Read: Understanding Biosimilars: Better Access to Advanced Medicines >>
No. Insurance companies now understand the role of biosimilars, and they get that everybody (including insurers) benefits from having more treatment options. In my experience, they’re very comfortable with covering biosimilars, but which biosimilars are covered will vary according to a person’s insurance plan.
Biosimilars have ushered in an era of expanded possibilities for cancer treatment. The type of biosimilar now used the most for cancer treatment is monoclonal antibodies. These medicines work by binding to a certain protein on a cancer cell, helping to block signals for cancer growth.
One is called bevacizumab, and it’s used to treat metastatic colon cancer, lung cancer and kidney cancer. Others we use are trastuzumab to treat HER2-positive breast cancer, and rituximab to treat non-Hodgkin’s lymphoma.
We also use biosimilars to provide supportive care to patients with cancer. One called epoetin helps with anemia caused by chemotherapy, and another called filgrastim is used for neutropenia (low white blood cell counts).
Questions you could ask are:
It’s our job as providers to make sure our patients know they have choices in their treatment and to have all the information they need about these choices.
Biosimilars have opened up cancer treatment opportunities for patients not just in the United States, but throughout the world. They’ve really been the unsung heroes of modern cancer treatment.
This educational resource was created with support from Sandoz.
From Your Site Articles
Related Articles Around the Web
Neha Bhasin was a part of India’s first all-girls pop group Viva. After a Channel V executive made disrespectful comments about her body in a room full of people, the singer attempted suicide by consuming more than half a bottle of fat burners.
Popular female playback singer Neha Bhasin is known for her several hit Bollywood songs including Jag Ghoomeya in Sultan, Kuch Khaas Hai in Fashion, Dhunki in Mere Brother Ki Dulhan, and Chashni in Bharat. Her singing journey began at the age of 18 when she won the singing reality show Channel V’s Coke [V] Popstars in 2002, along with four other young singers – Seema Ramchandani, Pratichee Mohapatra, Mahua Kamat and Anushka Manchanda. They formed India’s first all-girls music group Viva.
In a podcast with comedians Bharti Singh and Haarsh Limbachiyaa earlier this year, Neha recalled that she was put on fat burners a year after becoming a part of Viva. She shared that she was unaware of their effects at such a young age. She also recalled a shocking incident when one of the executives from Channel V made disrespectful comments about her body in a room full of people.
“He paused a music video, circled my stomach on screen, and said ‘See, you are so fat. Because of this, we can’t release the video.’ I was 50 kg at that time. I remember going home and, in anger, consuming more than half a bottle of fat burners. That was my way of trying to commit suicide. For two days, I was throwing up. The band did not know what had happened”, Neha stated.
While everyone knows about her singing career, not many know that Neha Bhasin also tried her hand at acting. She starred in the 2012 black comedy film Life Ki Toh Lag Gayi, that also featured Kay Kay Menon and Ranvir Shorey. The movie received horrible reviews from the audiences and critics, and bombed at the box office. The singer was also a part of the controversial reality shows Bigg Boss OTT Season 1, hosted by Karan Johar, and Bigg Boss 15, hosted by Salman Khan, in 2021.
Cardano (ADA) is largely in bearish hands, trading above support at $0.45 at the time of writing on Tuesday. The downtrend builds on a bearish outlook that has weighed on the smart contracts token since July, when ADA peaked at $1.02.
Bitcoin’s falling further, down 25% from its record high of 126.2k at the start of October, dropping to a low of 89.1k today, a level last seen in April. The largest cryptocurrency has fallen in seven of the past eight sessions, a losing streak that has left it trading in the red for 2025.

Bitcoin (BTC) is trading above $91,000 at the time of writing on Tuesday, down slightly on the day but trimming some earlier losses, weighed by risk-off sentiment in the broader cryptocurrency market. Altcoins, including Ethereum (ETH) and Ripple (XRP), are showing signs of mild recovery, hovering above $3,000 and around $2.18, but the broader trend remains bearish.

Testosterone isn’t only a “men’s hormone” — women make it too, just in much smaller amounts. In women, testosterone helps with sexual desire and arousal and plays a role in bone, muscle and brain health. Many experts agree the evidence points to using testosterone therapy in women to treat low sexual desire that is upsetting or distressing after menopause, a condition called hypoactive sexual desire disorder (HSDD).
There’s no FDA‑approved testosterone made just for women in the United States yet, so care can feel confusing. Here’s what you should know.
What is testosterone?
Testosterone is one of the body’s sex hormones that plays a big role in the reproductive system for both men and women. “In women, we think it might be important for bone mass, mood and other areas of health, but we’re still figuring that out,” said Nora Lansen, M.D., a family physician and chief medical officer at Elektra Health.
A lot more is known about testosterone’s direct effects for men, including its strong impact on libido, bone mass, mood and muscle growth, explained Lansen. “Average levels are about 10 to 20 times higher in men than in women,” she said.
For women, testosterone levels slowly decline with age, reach a low point in the late 50s, then rise slightly again. Research shows this pattern has more to do with age than with the menopause transition itself.
What is testosterone used for?
Testosterone is best supported for postmenopausal women with low sexual desire that is upsetting or distressing, after a full check of other causes like medications, sleep, mood, pain and relationship factors, said Sameena Rahman, M.D., an OB‑GYN and sexual medicine specialist. Major medical groups including The Menopause Society follow this approach and advise careful dosing and monitoring.
Lansen noted that treatment is personal and that desire can be influenced by other factors. If a woman’s testosterone levels are normal or high, putting additional testosterone into her system would be neither safe nor helpful, she explained. While testosterone is most often prescribed postmenopause, Lansen said it may be considered for women in late perimenopause on a case-by-case basis after evaluation and lab review.
How testosterone therapy works
Before any prescription, your healthcare provider (HCP) should look at the whole picture. If low desire is still upsetting after that workup, testosterone may be considered for HSDD.
Forms and doses
In line with the International Society for the Study of Women’s Sexual Health (ISSWH), most experts prescribe very low-dose skin gels or creams that were designed for men but given at a fraction of the male dose. Many start their patients around one-tenth (some use even less) and adjust slowly. A small, measured amount is applied once a day to clean skin, such as the thigh. Pellets are usually avoided because they cannot be adjusted or removed and may raise levels too high, said pharmacist Jobby John, PharmD, founder of compounding pharmacy Lake Hills in Bee Cave, Texas.
Metered dosing helps
Compounded, metered‑dose devices let each “click” equal one dose, which cuts down on measuring errors and lowers transfer risk, noted John. Some providers also use tiny vaginal tablets for local tissue effects when appropriate, which are made per‑patient with a valid prescription, and should follow specific quality standards, John said.
Monitoring and safety
HCPs often check total testosterone about three to six weeks after starting or changing a dose, then every four to six months when stable. The goal is to keep levels in a normal premenopausal range and watch for side effects. Call your HCP if you notice:
We do not yet know the long-term effects on the heart, brain, bones or breast tissue. Practice shared decision-making with your HCP to determine whether the benefits of using testosterone outweigh the risks for you.
Insurance and cost
Because there is no FDA-approved testosterone for women in the U.S., the medicine is often not covered by insurance. Office visits and labs may be covered. “Compounded testosterone is almost never covered by insurance, and most women pay about $45 to $90 per month, depending on the formula,” said John. Coupons may lower the cost of male-labeled gels used at very low doses.
Access and equity
Off-label status and cash-pay costs make care harder for people with lower incomes and those who live far from specialty clinics. Research shows there are already gaps in menopause care by race and income. Women of color are less likely to be offered or to receive standard hormone therapy, and cost, bias and medical mistrust can all play a role in those disparities.
When a treatment is off‑label and cash‑pay, those gaps can widen. “Although it’s really great that menopause is a topic being increasingly discussed in the media, it’s not fair to provide menopause information to all but reserve treatment for only those who can afford it,” said Lansen.
If cost or access is a barrier, ask about:
The future of testosterone therapy for women
Researchers are working on women-specific formulations and better long-term safety data. Australia already has a testosterone cream dosed for women, and some experts want an FDA‑approved option in the U.S. so dosing and access are clearer. Until then, care will likely remain off‑label, with careful monitoring and attention to equity and cost.
From Your Site Articles
Related Articles Around the Web
Toncoin was hit with what it described as a “major outage,” while Arbitrum’s block explorer, Arbiscan, also went down on Tuesday, as per a Coindesk report. Other websites, including social media platform X (Twitter) and data site DefiLlama, displayed intermittent “internal server errors” as the outage unfolded, as per the report.
Cloudflare acknowledged the problem at 11:48 UTC, saying that, “Cloudflare is aware of, and investigating an issue which impacts multiple customers: Widespread 500 errors, Cloudflare Dashboard and API also failing,” as quoted by the CoinDesk report.
ALSO READ: What is Cloudflare? How a major outage crashed parts of the internet and made X go down today
A 500 error typically signals an internal server issue that prevents a website from loading, so that means that website users will not be able to access a web page as long as the error persists, as per the report.
The disruption comes only weeks after Amazon Web Services (AWS) suffered a major outage of its own, which knocked thousands of websites and applications offline, as per the CoinDesk report. Platforms affected during that incident included Coinbase’s trading service, its Base layer-2 network, and the trading app Robinhood, as per the report.ALSO READ: Bull or bear market? Investors are tracking two key events – Nvidia earnings and September jobs report
Crypto exchange BitMEX also reported that it was investigating an outage linked to the latest Cloudflare issues, as reported by CoinDesk.
The internet services company previously announced NET Dollar, a US dollar–backed stablecoin, in September, although it has yet to launch, as per the report.
Cloudflare Inc (NET) shares fell 3.5% in pre-market trading following the outage, reported CoinDesk.
Is X (Twitter) down because of Cloudflare?
Yes, X saw intermittent internal server errors linked to the Cloudflare outage.
Is Cloudflare fixing the outage?
Cloudflare said it is investigating the issue and working on a fix.
The GBPJPY pair continued providing positive trading, noticing its stability above 203.95 and recording some gains by its rally towards 204.50, but stochastic negativity by its attempt to surpass the overbought level that might decelerate the bullish rally in the current period trading.
All that make us prefer the sideways trading, reminding you that the stability above the support at 201,70 forms a main factor for confirming the dominance of the bullish track, therefore, we will keep waiting for gathering extra bullish momentum to ease the mission of recording positive gains by its rally towards 205.25.
The expected trading range for today is between 203.35 and 204.65
Trend forecast: Fluctuated within the bullish track